| |
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
Today’s Big NewsJul 30, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates. Register Now! 
|
|
| By Zoey Becker For the first time since its sales peaked during the pandemic, Pfizer registered year-over-year revenue growth during the second quarter of 2024. And while the busy has been busy trimming operating expenses, it did add $1 billion to its total revenue projection for the year. |
|
|
|
By Nick Paul Taylor Pfizer’s phase 3 Duchenne muscular dystrophy (DMD) gene therapy failure has blown a $230 million hole in the New York pharma's second quarter financials. The drugmaker disclosed the discontinuation of the candidate—and the financial fallout—alongside the axing of a respiratory syncytial virus (RSV) combination vaccine. |
By James Waldron For the second quarter in a row, Incyte has used its earnings results to significantly slim down its early-stage pipeline as the Jakafi-maker channels its resources toward “high potential impact programs.” |
By Angus Liu Incyte is gunning for a first-in-class nod for its PD-1 inhibitor Zynyz in anal cancer again after being turned away by the FDA in 2021. But regulatory uncertainties remain. |
|
Sept. 25 - 26, 2024 | San Diego, CA Cutting-edge educational sessions: Gain insights from industry leaders. Early Bird Rate ends August 2nd, Save $400, Register Today! .png)
|
|
By Conor Hale The Alphabet company once synonymous with Silicon Valley's penchant for moonshot startup projects, Verily will now move its South San Francisco HQ to the "business-friendly" Dallas area, after it simplified its portfolio last year. |
By Nick Paul Taylor Eli Lilly has given 24 U.S. health equity charities an extra reason to keep an eye on the 2024 Olympics and Paralympics, agreeing to donate $5,000 each time Team USA wins a medal or breaks a record. |
By Kevin Dunleavy On a day when Merck reported strong sales for its launch of pulmonary arterial hypertension (PAH) treatment Winrevair (sotatercept) and stalwart cancer medicine Keytruda, the positive news was overshadowed by the suddenly flat sales of Gardasil. |
By Kevin Dunleavy With the BIOSECURE Act on the verge of passage and bringing with it the threat of crippling the business of four Chinese companies, the largest of the group, manufacturing powerhouse WuXi AppTec has reported a revenue decline. In the first half of 2024, sales for WuXi AppTec fell by 9%, to 17.2 billion yuan ($2.4 billion) year over year. |
By Nick Paul Taylor BioNTech has posted an early win for BNT111, linking a combination of the cancer vaccine candidate and Regeneron’s checkpoint inhibitor Libtayo to a better response rate than a historical control in melanoma patients. |
By Darren Incorvaia An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed cognitive decline by 18%. |
By Conor Hale Describing the technology as a way to reconnect people with paralysis to fast-moving consumer tech, Synchron is pitching a Bluetooth standard for computer interactions that doesn't require touch or speech. |
By Andrea Park Nearly three years after its debut, the Genentech-backed song “Spaces” made it to perhaps its biggest stage yet. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “Podnosis,” Micky Tripathi, Ph.D., National Coordinator for Health Information Technology at HHS, chats with Executive Editor Heather Landi about ONC’s achievements over the past 20 years, the agency’s current top priorities, the rapid adoption of AI in healthcare and more. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now. 
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
